Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3546 |
|
| Actual shortage: | 240 (7%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3292 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2019-12-05 | 2019-12-23 | 100314 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2020-12-11 | 2021-01-11 | 130065 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2021-03-19 | 2021-05-03 | 136030 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2021-04-09 | 2021-04-19 | 137267 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2021-05-25 | 2021-06-28 | 139851 |
| APO-PRAVASTATIN | 20MG | TABLET | Resolved | 2021-07-09 | 2021-10-05 | 142280 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2021-08-16 | 2021-09-27 | 144186 |
| APO-PRAVASTATIN | 20MG | TABLET | Resolved | 2021-08-16 | 2021-10-05 | 144189 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2021-08-16 | 2021-10-05 | 144204 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2022-02-25 | 2022-03-25 | 155606 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2022-02-25 | 2022-03-28 | 155609 |
| APO-PRAVASTATIN | 20MG | TABLET | Resolved | 2022-09-23 | 2022-11-04 | 170112 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2022-10-07 | 2022-11-04 | 171427 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2022-11-11 | 2023-01-21 | 174329 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2022-11-27 | 2022-12-23 | 175892 |
| APO-PRAVASTATIN | 20MG | TABLET | Resolved | 2022-12-23 | 2023-01-20 | 179459 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2024-02-02 | 2024-04-12 | 218397 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2024-02-02 | 2024-04-05 | 218400 |
| APO-PRAVASTATIN | 40MG | TABLET | Resolved | 2024-03-22 | 2024-04-12 | 223064 |
| APO-PRAVASTATIN | 10MG | TABLET | Resolved | 2024-03-27 | 2024-04-05 | 223549 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |